| Erika Ebane Mengalle, DO | |
|
593 Eddy St, Providence, RI 02903-4923 | |
| (401) 444-3985 | |
| Not Available |
| Full Name | Erika Ebane Mengalle |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518427376 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | DO01166 (Rhode Island) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
Argon Medical Devices, Inc. announced today that the company has begun marketing the CLEANERXT Rotational Thrombectomy System as a new addition to the CLEANER family of dialysis products.
The study published in "Angewandte Chemie" might help to work out strategies for developing potential drugs. As the team of scientist including Markus Zweckstetter and Eckhard Mandelkow report, methylene blue inactivates molecular residues that promote the bonding of tau proteins.
Researchers in the United States say one of the reasons why many patients do not do well after blood transfusions is because donated blood rapidly loses some of its life-saving properties.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erika Ebane Mengalle, DO 117 Ellenfield St Ste 101, Providence, RI 02905-4541 Ph: () - | Erika Ebane Mengalle, DO 593 Eddy St, Providence, RI 02903-4923 Ph: (401) 444-3985 |
News Archive
Argon Medical Devices, Inc. announced today that the company has begun marketing the CLEANERXT Rotational Thrombectomy System as a new addition to the CLEANER family of dialysis products.
The study published in "Angewandte Chemie" might help to work out strategies for developing potential drugs. As the team of scientist including Markus Zweckstetter and Eckhard Mandelkow report, methylene blue inactivates molecular residues that promote the bonding of tau proteins.
Researchers in the United States say one of the reasons why many patients do not do well after blood transfusions is because donated blood rapidly loses some of its life-saving properties.
Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but without the toxicity usually associated with cytotoxic or targeted treatments.
Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.
› Verified 3 days ago
Dr. Nabila Kabir Mazumder, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Providence, RI 02906 Phone: 401-793-2104 Fax: 423-793-4047 | |
Dr. Muyide Olujola Satiregun, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 252 Dudley St, Providence, RI 02907 Phone: 346-308-4623 | |
Dr. Syed M. Yunus Raza Naqvi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Providence, RI 02906 Phone: 401-793-4489 | |
Lloyd Patashnick, MD Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 164 Summit Ave, Providence, RI 02906 Phone: 401-793-4489 Fax: 401-793-4047 | |
Dr. Nadeem Anis, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave., Providence, RI 02906 Phone: 401-793-2104 Fax: 401-793-4047 | |
Ali Mrad, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-3985 | |
Dmitry Drozhzhin, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 101 Dudley St, Providence, RI 02905 Phone: 401-453-7950 Fax: 401-453-7658 |